An antitumor activity associated with several bacterial pathogens, including Salmonella enterica serovar Typhimurium, has been reported; however, the underlying immunological mechanism(s) that lead to an antitumor effect are currently unclear. Furthermore, such pathogens cannot be used to suppress tumor growth because of their potential for causing sepsis. Recently, we reported the characterization of S. Typhimurium isogenic mutants from which Braun lipoprotein genes (lppA and B) and the multicopy repressor of high temperature requirement (msbB) gene were deleted. In a mouse infection model, two mutants, namely, lppB/msbB and lppAB/msbB, minimally induced proinflammatory cytokine production at high doses and were nonlethal to animals. We showed that immunization of mice with these mutants, followed by challenge with the wild-type S. Typhimurium, could significantly suppress tumor growth, as evidenced by an 88% regression in tumor size in lppB/msbB mutant-immunized animals over a 24-day period. However, the lppAB/msbB mutant alone was not effective in modulating tumor growth in mice, although the lppB/msbB mutant alone caused marginal regression in tumor size. Importantly, we showed that CD44 þ cells grew much faster than CD44 À cells from human liver tumors in mice, leading us to examine the possibility that S. Typhimurium might downregulate CD44 in tumors and splenocytes of mice. Consequently, we found in S. Typhimurium-infected mice that tumor size regression could indeed be related to the downregulation of CD44 high and CD4 þ CD25 þ T reg cells. Importantly, the role of lipopolysaccharide and Braun lipoprotein was critical in S. Typhimurium-induced antitumor immune responses. Taken together, we have defined new immune mechanisms leading to tumor suppression in mice by S. Typhimurium.
Introduction
Salmonella enterica serovar Typhimurium has been shown to possess antitumor activity in a mouse model, as well as the capability to selectively amplify within tumors and express therapeutic proteins. 1, 2 Reports have indicated that S. Typhimurium selectively infects and preferentially colonizes solid tumors of cancer patients, [3] [4] [5] making it potentially useful as a vehicle to target human tumors in vivo. 1, 2, [6] [7] [8] Furthermore, S. Typhimurium has a significant ability to infect nonphagocytic cells through the expression of a type-III secretion system, which facilitates bacterial penetration of host cells. 9 Salmonella Typhimurium releases lipopolysaccharide (LPS) during both in vitro and in vivo growth, 10 and its release is significantly enhanced during bacterial lysis after exposure to antibiotics or human serum. This enhanced LPS release causes septic shock. 11 Similarly, Braun lipoprotein (Lpp) is also a critical bacterial component in the induction and pathogenesis of septic shock. Similar to LPS, it induces the production of tumor necrosis factor-a and interleukin (IL)-6 in mouse and human macrophages ex vivo, 12, 13 and leads to lethal shock as a result of this cytokine production in both LPSresponsive and nonresponsive mice. 14 More importantly, Lpp synergizes with LPS to induce the production of proinflammatory cytokines in mice, because Lpp binds to toll-like receptor-2, whereas LPS binds to toll-like receptor-4 and CD14 to activate host cells. 15 The biological potency of LPS can be significantly reduced when the multicopy repressor of a high temperature requirement (msbB) gene is deleted from S. Typhimurium. 2 This gene codes for an enzyme that is responsible for adding myristic acid to the lipid A moiety of LPS. 16 Consequently, in our recent studies, we characterized isogenic mutants of S. Typhimurium that were deleted for Braun lipoprotein (lppA and B) genes in conjunction with the msbB gene. 16 We provided evidence that such mutants were highly attenuated in a mouse model of salmonellosis and produced minimal levels of proinflammatory cytokines and chemokines. 17 We predicted that the lpp/msbB mutants of S. Typhimurium would be excellent live-attenuated vaccine candidates. Indeed, mice immunized with such mutants were solidly protected against challenge with lethal doses of wild-type (WT) S. Typhimurium, in that the lppB/msbB and lppAB/ msbB mutants provided maximum protection. These two mutants were further characterized in terms of their immune responses in a mouse model 17 and were examined in this study for their antitumor activity.
CD4 þ CD25 þ T regulatory (T reg ) cells have been shown to be controlling self-reactive T cells by helping to maintain immunological self-tolerance 18, 19 and are hence a major obstacle in effective antitumor immunotherapy. 20, 21 CD4 þ CD25 þ T reg cells have been reported to be specifically recruited to tumor sites and to effectively block antitumor cytotoxic T-lymphocyte responses. Hence, the targeted removal or inactivation of CD4 þ CD25 þ T reg cells in animal models could lead to improved tumor immuno-surveillance, better vaccine efficacy and enhanced antitumor immunity. [22] [23] [24] Furthermore, CD44 is the principal receptor of the hyaladherin receptor family, and CD44-hyaluronan interactions mediate cell adhesion and migration in various physiological and patho-physiological processes. [25] [26] [27] [28] CD44 is expressed on many tissues in developing and adult humans, and it was described originally as a homing receptor required for binding of lymphocytes to high endothelial venules. 29, 30 CD44 has also been shown to be involved in lymphocyte activation in humans 31, 32 and in a mouse model. 33 CD44 expression by tumor cells can increase their interaction with endothelial cells and transmigration across an endothelial monolayer. Several reports have shown that CD44 inhibitors, including anti-CD44 monoclonal antibody and hyaladherin inhibitors, can be used to block tumor cell growth, invasion and metastasis. 34, 35 In this study, we showed that lpp/msbB mutants alone were not effective in suppressing tumor growth in mice. However, we observed a significant regression in the size of tumors implanted in mice first immunized with the lpp/ msbB mutants of S. Typhimurium and then challenged with WT S. Typhimurium. Furthermore, we noted a decrease in CD4 þ CD25 þ T reg cell numbers and a downexpression of CD44 high in the spleen of mice infected with S. Typhimurium, which for the most part could be mediated through LPS and Lpp.
Materials and methods

Bacterial cultures
The WT S. Typhimurium 14028 strain and its various mutants used in this study are listed in Table 1 . The organisms were grown in Luria-Bertani (LB) broth or on LB agar plates in the presence of appropriate antibiotics. For the growth of msbB mutants, we used a special MsbB medium as described earlier. 17 The MsbB medium/liter consisted of the following: 10 g tryptone, 5 g yeast extract, 1 ml 1 M MgSO 4 and 1 ml 1 M CaCl 2 . Bacteria were cultivated at 37 1C overnight with shaking at 200 r.p.m., harvested by centrifugation (6000 r.p.m. for 5 min), washed with phosphate-buffered saline (PBS) and resuspended in a minimal amount of PBS. Bacteria were counted by determining colony-forming units (cfu) in triplicate, and were expressed as cfu ml -1 .
Animals
We used 6-to 8-week-old C57BL/6, BALB/c and/or Swiss-Webster female mice (Taconic Farms, Germantown, NY). For selected studies, we used breeding pairs of IL-10 À/À mice in a C57BL/6 background (The Jackson Laboratory, Bar Harbor, ME) and IL-10 À/À aged mice (2-years old). We used IL-10 þ / þ and IL-10 À/À mice, as IL-10 is a pleiotropic cytokine with anti-inflammatory and antiangiogenic properties in in vitro and in vivo models. 36, 37 High IL-10 levels result in smaller tumors, in their lesser metastases and in reduced angiogenesis in humans, and low IL-10 production is associated with increased risk of prostate cancer. 38 Mice were kept under specific pathogen-free conditions in filter-topped cages with sterile bedding and were fed sterile food and water. Abbreviations: Kn r , kanamycin resistance; Nal r , nalidixic acid resistance; Tc r , tetracycline resistance.
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Infection/-immunization of mice Mice were infected-immunized through the intraperitoneal route with WT S. Typhimurium14028, the lppB/ msbB mutant and/or the lppAB/msbB mutant (Table 1) at doses ranging from 0.5 Â 10 2 to 2 Â 10 3 cfu/100 ml, and deaths were recorded for a 30-day period. In some cases, mice were initially immunized with mutant S. Typhimurium strains and then rechallenged with the WT S. Typhimurium strain (2 Â 10 3 cfu) 30 days after the initial immunization. The animal experiments were performed under the approved Institutional Animal Care and Use Committee, and death was the endpoint of the study when animals were infected with WT bacteria. However, animals that were immunized with mutant S. Typhimurium strains and then challenged with the WT bacterium survived and were humanely killed after 30 days.
Bacterial counts
At indicated time intervals after the infection-immunization of mice, spleens were removed and homogenized in PBS, and serial dilutions of the homogenates were plated on LB and Salmonella-Shigella agar plates to determine bacterial counts. The plates were incubated at 37 1C for 24-48 h and colonies were counted.
Tumor cells
The B16F1 melanoma cell line from ATCC (American Type Culture Collection, Manassas, VA) was cultured in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin and 2 mM of L-glutamine before injecting into mice under an approved animal protocol. These cells were grown for 6 days at 37 1C in the presence of 5% CO 2 before injections. Human liver cancer cells (from the Sealy Cancer Center, University of Texas Medical Branch, Galveston, TX) were stained with mouse anti-human CD44 PE antibody (PE, clone 515) (BD Bioscience, Franklin Lakes, NJ). After washing with PBS, CD44 þ and CD44 À tumor cells were isolated using a FACSAria (BD Bioscience). Each cell clone population was expanded in Dulbecco's Modified Eagle's Medium supplemented with 10% fetal bovine serum, 100 U ml -1 penicillin, 100 mg ml -1 streptomycin and 2 mM of L-glutamine in 96-well tissue culture microtiter U-bottom plates.
Tumor cell injections
In all, 6-to 8-week-old female C57BL/6 mice were subcutaneously (s.c.) injected with tumor cells at 5 Â 10 5 /mouse/100 ml. Personnel blinded to the study design measured tumor growth by microcaliper thrice a week. Tumor volume was calculated according to the following formula: (length) Â (width) Â (width)/2.
Flow cytometric analysis
Spleen cells were obtained from mice infected with WT or with mutant strains of S. Typhimurium. Splenocytes (10 5 ) were suspended in PBS and 1% fetal bovine serum, and incubated with mouse CD16/CD32 monoclonal antibodies (0.25 mg/100 ml) (BD Bioscience) for 15 min at room temperature. These antibodies were added to block antibody binding to mouse Fc-g receptor-bearing cells. The cells were then washed twice with PBS plus 1% fetal bovine serum. To quantitate T cells, the cell suspension was incubated for 60 min at 4 1C with anti-CD4 (BD Bioscience, clone GK1.5) antibody conjugated to fluorescein isothiocyanate (FITC) (0.25 mg/100 ml), with anti-CD44 (BD Bioscience, clone IM7) antibody conjugated to phycoerythrin (PE) (0.1 mg/100 ml) and with anti-CD25 (BD Bioscience, clone 3C7) antibody conjugated to antiallophycocyanin (0.1 mg/100 ml). Subsequent to incubation, the cells were washed twice with PBS and then analyzed by FACScan flow cytometry using CellQuest (Becton Dickinson, Mountain View, CA) software. The corresponding isotype controls (rat IgG1, IgG2a and IgG2b) were purchased from eBioscience (San Diego, CA) and BD Bioscience, respectively.
Statistics
At least three independent experiments were performed, and data were analyzed using Student's t-test. P-values of p0.05 were considered significant. Statistically significant values are referred to as follows: *Po0.05; **Po0.01; and ***Po0.001.
Results
Effect of WT S. Typhimurium and its lpp/msbB mutants on tumor growth We opted to immunize mice with various S. Typhimurium strains before transplantation of tumors, as we did not intent to develop tumor-antigen-specific immune-memory response, which could potentially interfere with S. Typhimurium-induced strong cellular and humoral immune responses. Furthermore, as discussed in the next section, it was important to immunize animals with mutant S. Typhimurium strains, as we could use high doses of them without inducing any lethality and then challenge mice with a high dose of WT bacteria, which otherwise will be lethal to animals in an unimmunized group. Finally, people traveling from the developed world to developing countries are invariably vaccinated with the live-attenuated Salmonella strain and therefore it seemed logical to immunize animals with S. Typhimurium.
To delineate whether WT S. Typhimurium or its mutant strains suppressed the growth of melanomas, mice were infected with 50 cfu per mouse of either WT S. Typhimurium or its lppAB/msbB or lppB/msbB mutant strain. Mice injected with PBS served as negative control. After 30 days, B16 cells (5 Â 10 5 ) were subcutaneously injected into mice. The mean tumor size for various bacterial strains after 24 days was as follows: WT S. Typhumirum, 640±52 mm 3 ; lppB/msbB mutant, 798 ± 65 mm 3 ; lppAB/msbB mutant, 871 ± 62 mm 3 ; and PBS, 912 ± 74 mm 3 (Figure 1a ). As can be noted from this figure, tumor size was inhibited in WT S. Typhimuriuminfected mice by a statistically significant 30% compared with the rate in animals that were given PBS alone. The decreased tumor size was only marginal (12%), however, Typhimurium suppresses tumor growth in mice infected with the lppB/msbB mutant after 24 days, and was nonexistent for up to 21 days in animals infected with the lppAB/msbB mutant when compared with PBS controls. A slight, but statistically insignificant, decrease in tumor size occurred after 24 days with the lppAB/msbB mutant ( Figure 1a ).
Consequently, we further analyzed, using a different approach, the antitumor effects of WT S. Typhimurium and its mutants. In this set of experiments, mice were immunized with lppAB/msbB and lppB/msbB mutants of S. Typhimurium at a dose of 2 Â 10 3 cfu. Our earlier studies indicated that mice were fully protected against mortality by intraperitoneal doses of up to 1 Â 10 6 -1 Â 10 7 cfu of these mutants and showed that animals immunized with the above mutants at doses of 1 Â 10 6 -1 Â 10 7 cfu were 100% protected against similar doses of WT bacteria after rechallenge. 17 After 30 days of immunization of these mice with the above mutants, we rechallenged them with WT S. Typhimurium at a dose of 2 Â 10 3 cfu. Two weeks after the rechallenge of mice with WT bacteria, B16 cells (5 Â 10 5 ) were implanted s.c. into the animals. The mean tumor sizes in mice immunized with the mutants, followed by WT infection, were as follows: lppAB/msbB mutant alone, 863 ± 71 mm 3 ; lppB/msbB mutant alone, 660 ± 49 mm 3 ; lppAB/msbB þ WT, 470±31 mm 3 ; and lppB/msbB þ WT, 110 ± 9 mm 3 (Figure 1b ). The tumor size in mice injected with PBS alone was 903 ± 86 mm 3 and served as a positive control. It is evident from these data that tumor size regressed in the animals first immunized with the mutants and then challenged with WT S. Typhimurium, and that lppAB/msbB and lppB/msbB mutants, respectively, provided 48 and 88% protection. The protection afforded by lppB/msbB and lppAB/msbB mutants alone at a dose of 2 Â 10 3 cfu was 27 and 5%, respectively ( Figure 1b ).
Infection of mice with WT S. Typhimurium and its lppB/ msbB mutant downregulated the expression of CD4 þ CD25 þ T reg cells To define the underlying mechanism(s) involved in S. Typhimurium-induced tumor growth suppression, we infected Swiss-Webster mice with WT S. Typhimurium or its lppAB/msbB and lppB/msbB mutants (1 Â 10 3 cfuper mouse). After 5 days of infection, spleens from infected mice were stained with anti-CD4 FITC and anti-CD25 allophycocyanin, and splenocytes were analyzed by flow cytometry. We found that CD4 þ CD25 þ T reg cells decreased significantly in the WT group of infected mice (0.5%) compared with uninfected animals (1.6%, a decrease of 69%) (Figure 2a ). The number of CD4 þ CD25 þ T reg cells decreased slightly by 31% in mice infected with the lppB/msbB mutant (1.1 vs 1.6% for control), and was minimally affected (1.5%) in lppAB/ msbB-infected mice compared with controls (1.6%). The percentage of CD4 þ cells was slightly decreased in animals infected with WT S. Typhimurium (18%) when compared with animals infected with either the lppB/msbB (21%) or lppAB/msbB (22%) mutant and/or those mice that were only given PBS (24%). In addition, we found that the expression of gene-encoding Forkhead box P3, which controls T reg cell development and their functions, 39 was downregulated in splenocytes of mice infected with WT S. Typhimurium (0.6%), when compared with splenocytes of control uninfected mice (1.8%). As a positive control, we used splenocytes treated with S. Typhimurium LPS (3 mg ml -1 ), which, as expected, decreased the expression of gene-encoding Forkhead box P3 significantly (0.31%) compared with controls ( Figure 2b ). Some downregulation of T-cell activation Figure 1 Suppression of tumor growth in C57BL/6 mice by wildtype (WT) Salmonella Typhimurium and its lpp/msbB mutants. (a) C57BL/6 mice (n ¼ 5 per group) were infected through the intraperitoneal (i.p.) route with 50 cfu/100 ml of WT S. Typhimurium or its lppAB/msbB and lppB/msbB mutants, with mice receiving PBS as a control. After 30 days, B16 melanoma cells (5 Â 10 5 /100 ml) were subcutaneously injected into mice, who were observed over a period of 24 days. (b) Mice were immunized with the lppAB/msbB or the lppB/msbB mutant at a dose of 2 Â 10 3 cfu. After 30 days, these mice were rechallenged with WT S. Typhimurium at a dose of 2 Â 10 3 cfu. Two weeks later, B16 cells were subcutaneously injected into mice and the sizes of tumors were monitored over a period of 24 days. The mean tumor size ± standard deviation is presented. These profiles are representative results from three independent experiments. Statistically significant data are indicated by asterisks (*Po0.05, **Po0.01 and ***Po0.001).
(20%) was also detected in splenocytes infected with WT S. Typhimurium ex vivo.
Immunization of mice with the lppAB/msbB mutant, followed by challenge with WT S. Typhimurium, increased the number of CD4, CD4 þ CD25 þ T reg and natural killer (NK) cells, as well as macrophages, in the tumor of mice. An important question that should be considered is whether there are increases in T-and/or NK-cell lytic activity against B16 melanoma cells in mice that were first immunized with the S. Typhimurium mutant (for example, lppAB/msbB) and then challenged with WT S. Typhimurium compared with mice that were immunized with the mutant but challenged with the same lppAB/msbB mutant. The above-mentioned scenarios would lead to reduced tumor growth. Therefore, we immunized C57BL/6 mice with the lppAB/msbB mutant at a dose of 2 Â 10 3 cfu. After 30 days, we challenged them with WT S. Typhimurium at a similar dose of 2 Â 10 3 cfu. After 2 weeks, B16 cells (5 Â 10 5 ) were implanted s.c. into the animals, and 3 weeks later, tumor cells from these mice were stained with CD4-PE-Cy7, CD25-allophycocyanin, NK1.1-FITC, CD11b-PE, CD3-PE and interferon (IFN)-gÀFITC antibody and analyzed by flow cytometry. Our data indicated that the number of CD4, CD4 þ CD25 þ and NK cells, as well as macrophages, was increased to 1.8, 3.2, 2.6 and 7%, respectively, in tumors of mice that were first immunized with the lppAB/ msbB mutant before WT S. Typhimurium challenge. These numbers were in contrast to 0.1, 0.4, 0.5 and 1.5% in animals that were immunized with the mutant and then challenged with the mutant. Similarly, animals that were given only PBS had the following percentages of CD4, CD4 þ CD25 þ , NK and macrophages: 0.1, 0.3, 0.2 and 1.6%, respectively. Importantly, the percentage of IFN-gproducing T cells that infiltrated into the tumor of mice that were first immunized with the lppAB/msbB mutant and then challenged with WT S. Typhimurium was also much higher compared with that of tumors of mice that were immunized with the lppAB/msbB mutant and subsequently challenged with the mutant. Animals given only PBS but injected with B16 cells had a baseline level of IFN-g (Figures 3a-c) .
The WT and lpp/msbB mutants of S. Typhimurium downregulated the expression of CD44 in mouse melanoma B16 cells in vitro and in the spleens of mice in vivo. We cultured B16 cells with WT S. Typhimurium or its lppAB/msbB and lppB/msbB mutants at a multiplicity of infection of 1 in Dulbecco's Modified Eagle's Medium at 37 1C in the presence of 5% CO 2 . After 24 h of incubation, cells were harvested and stained with mouse anti-CD44 PE and analyzed by flow cytometry. As noted from Figure 4a , WT S. Typhimurium-infected B16 cells showed a significant decrease in the expression of CD44 marker (69%) compared with that of control (83%). Similarly, the expression of CD44 showed a downward trend, with decreases to 74 and 71% in B16 cells infected with the lppAB/msbB and lppB/msbB mutant, respectively, compared with uninfected B16 cells (83%).
We also infected Swiss-Webster mice with WT S. Typhimurium or its lppAB/msbB and lppB/msbB mutants (1 Â 10 3 cfu per mouse). After 5 days of infection, spleen cells were stained with anti-CD44 PE and analyzed by flow cytometry. As noted from Figure 4b , the splenocytes of the WT S. Typhimurium-infected group showed a significant decrease (3.4 vs 12.6%; indicated by an arrow) in the expression of CD44 high , followed by lppB/msbB (6.5%) and lppAB/msbB (9.7%) mutants, compared with control splenocytes from uninfected mice.
CD4 T reg cells in CD44 high cells from spleens of naive C57BL/6 mice and IL10 À/À aged mice Splenocytes from naive C57BL/6 and IL10 À/À aged mice were stained with mouse anti-CD4 FITC, anti-CD25 allophycocyanin and anti-CD44 PE antibodies, and were analyzed by flow cytometry. R1 cells were gated as lymphocytes and R1 þ R2 as CD44 high cells, although R1 þ R3 represented CD44 med cells (Figure 5a ). CD44 high cells contained much higher levels of CD4 þ CD25 þ T reg cells (1.82%), compared with the levels in CD44 med (1.13%) and control splenocytes (1.61%) of naive C57BL/ 6 mice (Figure 5b ). In IL-10 À/À aged mice, CD44 high cells contained much higher levels of CD4 þ CD25 þ T reg cells (2.3%) compared with the levels in CD44 med (0.7%) and control splenocytes (1.8%) (Figure 5c ).
Higher levels of CD44 high expression in spleens of IL-10 À/À aged mice Splenocytes from C57BL/6 and IL-10 À/À aged mice were stained with mouse anti-CD44 PE antibodies. Splenocytes from C57BL/6 aged mice expressed higher levels of CD44 than did those from young mice (Figure 6a ; 2.06 vs 3.97%). The splenocytes from IL-10 À/À aged mice expressed even higher levels of CD44 than did those from IL-10 À/À young mice (Figure 6b ; 2.5 vs 13.6%). We then subcutaneously implanted B16 tumor cells in IL-10 À/À aged mice. After 24 days, mice with bigger or smaller tumors were killed and their splenocytes were stained with mouse anti-CD44 PE antibodies. In general, mice having larger tumors expressed higher levels of CD44 high (12.5 vs 8.4%) than did animals with smaller tumors (Figure 6c ).
Growth of CD44 þ and CD44 À cells from human liver tumors in mice
We sorted CD44 þ and CD44 À cells from human liver tumors and grew them in Dulbecco's Modified Eagle's Medium. After expansion of cell colonies in 96-well microtiter plates, cells were transferred to 25-cm 2 cell culture flasks. Six days later, CD44 þ and CD44 À tumor cells (5 Â 10 5 /100 ml) were injected s.c. into BALB/c mice. The mean tumor size for the CD44 þ group was 1075 ± 175 mm 3 compared with 62 ± 42 mm 3 for the CD44 À group on day 20 after injection (Figure 7) . These data indicated that CD44 was required for tumor growth and represented an important tumor marker.
Discussion
The exact mechanism by which Salmonella strains result in an inhibition of tumor growth is still unclear. Some earlier studies reported the construction of mutant strains of S. Typhimurium, such as msbB and auxotrophic mutants that were nonpathogenic for mice, pigs and humans. These were also shown to have accumulated 1000-fold more in tumors than in other organs. However, the clinical application of such strains did not successfully curtail tumor growth. 2, 40 In this study, we showed that the lppAB/msbB mutant did not suppress tumor growth, although the lppB/msbB mutant did somewhat slow down the growth of tumors compared with those of controls in the 24-day observation (Figure 1a ). Importantly, tumor size in mice immunized with either of the mutants and then infected with WT bacteria was significantly reduced (Figure 1b) . These data indicated that the S. Typhimurium mutants that were deleted for the msbB and lpp genes lost this tumor repressor function, and LPS and Lpp were critical for S. Typhimurium's antitumor function. Figure 3 Infection of immunized mice with wild-type(WT) Salmonella Typhimurium increased the number of CD4, CD4 þ CD25 þ and NK cells, as well as macrophages, in tumors of mice. Mice were immunized with the lppAB/msbB mutant at a dose of 2 Â 10 3 cfu. After 30 days, these mice were challenged with WT S. Typhimurium or the lpp mutant at a dose of 2 Â 10 3 cfu. Two weeks later, B16 cells were subcutaneously injected into mice, and 3 weeks later, tumor cells were removed and stained with CD4-PE-Cy7, CD25-allophycocyanin (APC), NK1.1-fluorescein isothiocyanate (FITC), CD11bphycoerythrin (PE), CD3-PE and interferon (IFN)g-FITC antibody for analysis by flow cytometry. These profiles are representative results from three independent experiments. Statistically significant data are indicated by asterisks (**Po0.01, ***Po0.001).
The CD4 þ CD25 þ T reg cells have a crucial role in tumor immune pathogenesis, and they also modulate immune therapeutic efficacy. [41] [42] [43] [44] We explored the mechanism(s) underlying an S. Typhimurium-mediated, antitumor effect, and found that CD4 þ CD25 þ T reg cells from spleens of mice were significantly decreased (69%) in CD44 PE counts Figure 4 The wild-type (WT) Salmonella Typhimurium and its lpp/msbB mutant strains downregulated the expression of CD44 in B16 tumor cells and in the splenocytes of mice. (a) B16 cells were infected with WT S. Typhimurium or its lppB/msbB and lppB/msbB mutants. After 24 h, the cells were stained with mouse anti-CD44 PE. (b) Swiss-Webster mice (n ¼ 3 per group) were treated with WT S. Typhimurium or its lppB/ msbB and lppB/msbB mutants, with uninfected mice as negative controls. After 5 days, splenocytes from infected and uninfected mice were stained with mouse anti-CD4 phycoerythrin (PE) antibody and data were analyzed by flow cytometry. An isotype control is shown as a lightcolored line on the left of each panel. These profiles are representative results from three independent experiments. 10 0 10 4 10 3 10 2 10 1 10 0 10 4 10 3 10 2 10 1 10 0 10 4 10 3 10 2 10 1 10 0 Figure 5 The population of CD4 þ CD25 þ T reg cells in CD44 high cells from spleens of C57BL/6 and IL-10 À/À aged mice. Splenocytes from C57BL/6 and IL-10 À/À aged mice (n ¼ 3 per group) were stained with mouse anti-CD44 PE, anti-CD4 FITC and anti-CD25 allophycocyanin (APC) antibodies, and analyzed by flow cytometry. (a) CD44 med and CD44 high cells were gated. In splenocytes, R1 ¼ lymphocytes, R1 þ R2 ¼ CD44 high cells and R1 þ R3 ¼ CD44 med . (b) CD4 þ CD25 þ CD44 cells in C57BL/6 mice. (c) CD4 þ CD25 þ CD44 cells in IL-10 À/À aged mice. These profiles are representative results from three independent experiments.
Typhimurium suppresses tumor growth T Liu and AK Chopra WT S. Typhimurium-infected mice and decreased by 31% in lppB/msbB mutant-infected mice (Figure 2a ). This decrease in T reg cell development correlated with the decreased Forkhead box P3 expression in splenocytes of mice infected with WT S. Typhimurium (Figure 2b) . LPS has been shown to reduce the expression of Forkhead box P3 in lymphocytes. 45, 46 Our data presented in Figures 2a and 4b tend to suggest that the expression of CD44 high on T cells could in part be related to both T-cell activation and T reg -cell population. We must emphasize here that for some experiments we preferred to use out-bred Swiss-Webster over in-bred C57BL/6 mice, as the latter are more sensitive to S. Typhimurium infection, because as little as 50 cfu resulted in the deaths of 30-50% of these mice. Therefore, in those experiments in which higher doses of bacteria were used, we used Swiss-Webster mice.
We should cautiously interpret data, as different strains of mice might behave differently to S. Typhimurium infection as it relates to tumor growth.
Salmonella Typhimurium-induced CD8 cytotoxic T-lymphocyte and NK cells can kill tumor cells directly. [47] [48] [49] Similarly, S. Typhimurium promotes the maturation of dendritic cells and enhances the ability of antigens to present to dendritic cells . 50 It has been shown that splenic T cells are broadly activated in the host later during Salmonella infection. 51 Further, salmonellae-induced IL-12 and IFN-g are two critical antitumor cytokines, 52 and IFNg-producing T cells are significantly elevated after primary infection. 53 Our results showed that CD4, CD4 þ CD25 þ and NK cells, as well as macrophages, were significantly increased in tumors of mice that were first immunized with the lppAB/msbB mutant and then challenged with WT S. Typhimurium compared with those animals that were only immunized or given PBS (Figure 3 ). It is known that CD4 and NK cells could inhibit tumor growth, 54, 55 but the function of CD4 þ CD25 þ cells in modulating the growth of tumors is not clear. On the basis of our data, CD4 þ CD25 þ cells seemed to be recruited into tumors, but they might not inhibit tumor growth directly but might prevent suppressor CD4T cells from entering tumors. We found CD4 þ CD25 þ cell numbers to be lower in smaller size tumors than in bigger size tumors after infection of mice with WT S. Typhimurium (data no shown). Further, IFN-g producing cells were significantly increased in tumors that were first immunized with the lppAB/msbB mutant and then challenged with WT S. Typhimurium, suggesting that Th1 response might be important for the antitumor response.
CD44 has been shown to be highly expressed in many tumor cells, 56 such as colorectal cancer stem cells, and expression of CD44 in immortalized cancer cell lines is of functional importance. 57, 58 CD44 has recently been shown to be an important marker of cancer stem cells or cancer-initiating cells. 59, 60 Both CD44 and its variant (vCD44), when expressed in cancer cells, correlate counts Figure 6 Interleukin (IL)-10 À/À aged mice (n ¼ 10 per group) were subcutaneously injected with B16 tumor cells. After 24 days, the mice with bigger or smaller tumors were killed, and splenocytes were stained with mouse anti-CD44 PE antibodies. These stained cells were then analyzed with flow cytometry. Growth of human CD44 liver cancer cells in mice. Both CD44 þ and CD44 À cells from human liver cancer were sorted and subcutaneously injected into BALB/c mice (n ¼ 5 per group). The tumor size was measured over a period of 20 days. The mean tumor size ± standard deviation is presented. These profiles are representative results from three independent experiments. Statistically significant data are indicated by asterisks (***Po0.001).
strongly with invasiveness, metastasis and tumor growth. 61, 62 Similarly, CD44 þ cancer stem cells have been shown to have an enhanced potential for proliferation, migration and invasion. 63 We noted that CD44 was expressed at a significant level in B16 tumor cells. However, its expression was decreased in B16 tumor cells infected with S. Typhumirum, although to different levels with WT versus the mutants (Figure 4a ). The WT S. Typhimurium strains used in this study not only directly decreased the CD44 expression of tumor cells in vitro but also decreased the CD44 expression of lymphocytes in vivo (Figure 4b ). It has been shown in literature that LPS induces CD44 expression in monocytes; 64, 65 however, why then did CD44 cells decrease after S. Typhimurium infection in our study? We believe that activation-induced death of splenic cells could contribute to the observed CD44 cell loss during S. Typhimurium infection. The role of CD44 expression in the development of T reg cells has been reported, 66 and therefore, we analyzed CD44 high cells of spleens for the presence of CD4 þ CD25 þ T reg cells (Figure 5a ). We found that CD44 high cells contained much higher levels of CD4 þ CD25 þ T reg cells than did the CD44 med cells in C57BL/6 mice (Figure 5b) . Similarly, CD44 high cells contained much higher levels of CD4 þ CD25 þ T reg cells than did CD44 med cells in IL-10 -/mice (Figure 5c ).
Interleukin-10 has been shown to be associated with both immune stimulation and suppression of tumor growth. A high incidence of colorectal adenocarcinomas (60%) was observed in IL-10 À/À aged mice. The IL-10 -/mouse is a model for colon cancer, which develops through the dysphasia sequence, a process similar to that seen in clinical inflammatory bowel disease-associated cancer. 67, 68 Therefore, we next examined IL-10 À/À aged mice and found increasingly higher CD44 high levels in the splenocytes of aged IL-10 À/À mice than in young mice (Figure 6b ). Moreover, when we injected B16 tumor cells s.c. into IL-10 À/À aged mice and selected a few mice having either large or small tumors, we found a higher expression of CD44 high in spleens of mice having larger tumors than in those with smaller tumors (Figure 6c ). Aged mice have reportedly expressed higher levels of CD44 high than have younger mice (approximately twofold) (Figure 6a ). For example, the CD44 high expression was greater in aged SPA-1 À/À mice developing late-onset myeloid leukemia. 69 Thus, CD44 high cells may contribute to tumor occurrence and development. Therefore, the relationship of CD44 high expression of lymphocytes with tumor growth should be further studied in detail.
To confirm that CD44 is important for tumor growth, we sorted CD44 þ and CD44 À cells from human liver tumor samples. We found that CD44 þ tumor cells grew much faster compared with CD44 À tumor cells in vivo ( Figure 7) ; however, their growth rates were quite similar in vitro. These data suggested to us a dependence on CD44 in tumor development in vivo. CD44 is a cell surface proteoglycan, thought to be involved in cell-to-cell adhesion and cell matrix-adhesion interactions, lymphocyte activation, and homing and cell migration. We believe that S. Typhimurium suppresses tumor growth through various direct and indirect pathways, and that our data indicate that it directly downregulates the expression of CD44 in tumors in vitro and in lymphocytes in vivo. Furthermore, S. Typhimurium seemed to enhance the antitumor response by reducing the numbers of CD4 þ CD25 þ T reg cells.
We noted that lppAB/msbB and lppB/msbB mutants induced a very low Th1 response in mice, including minimal IFN-g and tumor necrosis factor-a production and higher levels of IgG1 antibody production, compared with WT S. Typhimurium-treated mice, which showed the opposite trend. 17, 70 These data suggested that Th1induced cellular responses were more important than antibody (humoral) responses in antitumor immune mechanisms. Would such mutants be beneficial in controlling tumor growth in humans? The advantage of immunizing first with the mutants is that subsequently higher doses of WT bacteria can be given without danger of inducing sepsis in the host. Certainly, this adjunct therapy would then seem to be advantageous, as the virulence of WT S. Typhimurium likely seems to be essential in retarding tumor growth in the host. The lpp/ msbB mutants in general and the lppAB/msbB mutant in particular caused a significant increase in the downregulation of CD44 and the number of CD4 þ CD25 þ T reg cells, when compared with WT S. Typhimurium in splenocytes of infected mice (Figures 2 and 4) . These data tend to suggest the role of LPS and Lpp in the downregulation of CD44 and T reg cells, with an ultimate reduction in the tumor suppression function of lpp/msbB mutants (Figure 1 ). An earlier study by Low et al. 2 reported that the S. Typhimurium msbB mutant did not alter antitumor activity against s.c. implanted B16F10 melanomas. 2 Therefore, Lpp might be more important in inducing an antitumor effect than LPS and would be studied in the future.
Recently, it was shown that the antitumor activity of Salmonella strains correlated with decreased angiogenesis and increased tissue necrosis within tumor tissue. 71 Their results showed that Salmonella could directly inhibit tumor growth. Our data pointed to the fact that S. Typhimurium not only directly inhibited tumor growth but also inhibited tumor growth indirectly through pathways. such as changes in the host immune system, specifically by downregulating CD44 and CD4T reg cell numbers in the spleen of mice.
In this study, we used S. Typhimurium mutants lppAB/ msbB and lppB/msbB as adjuncts to help WT S. Typhimurium suppress tumor cell growth. We found tumor growth suppression by 88% in mice that were first immunized with the lppB/msbB mutant and then challenged with 2 Â 10 3 cfu of WT S. Typhimurium. Our data provided possible mechanisms by which S. Typhimurium could modulate tumor growth, and included the downregulation of CD44 and CD4 þ CD25 þ T reg cell expression, which would, in turn, upregulate host immune responses to inhibit tumor growth that is largely LPS-and Lpp-dependent. The use of mutant S. Typhimurium to suppress tumor growth might provide attractive alternatives for the development of immunotherapy for cancer.
